JP6655090B2 - 神経精神系障害の治療のための組成物および方法 - Google Patents

神経精神系障害の治療のための組成物および方法 Download PDF

Info

Publication number
JP6655090B2
JP6655090B2 JP2017540782A JP2017540782A JP6655090B2 JP 6655090 B2 JP6655090 B2 JP 6655090B2 JP 2017540782 A JP2017540782 A JP 2017540782A JP 2017540782 A JP2017540782 A JP 2017540782A JP 6655090 B2 JP6655090 B2 JP 6655090B2
Authority
JP
Japan
Prior art keywords
disorders
treatment
acid
component
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503677A (ja
Inventor
トン ヒョン イ
トン ヒョン イ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2018503677A publication Critical patent/JP2018503677A/ja
Priority to JP2020015828A priority Critical patent/JP6943994B2/ja
Application granted granted Critical
Publication of JP6655090B2 publication Critical patent/JP6655090B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
JP2017540782A 2015-01-28 2016-01-28 神経精神系障害の治療のための組成物および方法 Active JP6655090B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020015828A JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562108616P 2015-01-28 2015-01-28
US62/108,616 2015-01-28
PCT/KR2016/000903 WO2016122218A2 (ko) 2015-01-28 2016-01-28 신경정신계 장애의 치료를 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020015828A Division JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2018503677A JP2018503677A (ja) 2018-02-08
JP6655090B2 true JP6655090B2 (ja) 2020-02-26

Family

ID=56544502

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017540782A Active JP6655090B2 (ja) 2015-01-28 2016-01-28 神経精神系障害の治療のための組成物および方法
JP2020015828A Active JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法
JP2021147148A Active JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法
JP2023085969A Active JP7594045B2 (ja) 2015-01-28 2023-05-25 薬学的組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020015828A Active JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法
JP2021147148A Active JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法
JP2023085969A Active JP7594045B2 (ja) 2015-01-28 2023-05-25 薬学的組成物

Country Status (8)

Country Link
US (4) US20170326127A1 (enExample)
EP (2) EP4385575A3 (enExample)
JP (4) JP6655090B2 (enExample)
KR (6) KR20220071297A (enExample)
CN (2) CN107206093A (enExample)
DK (1) DK3251699T3 (enExample)
ES (1) ES2985064T3 (enExample)
WO (1) WO2016122218A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200387A1 (en) * 2017-04-24 2018-11-01 Chase Therapeutics Corporation Compositions and method for treating depression
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
KR102176538B1 (ko) 2019-01-31 2020-11-09 한국과학기술연구원 항정신병성 약물 검출용 fret 바이오센서 및 이를 이용한 검출 방법
US20220280501A1 (en) * 2021-03-06 2022-09-08 Universitätsspital Basel Using geno- or phenotyping to adjust lsd dosing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
EP0840610A1 (en) * 1995-07-14 1998-05-13 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US20030114475A1 (en) * 2001-10-31 2003-06-19 Addiction Therapies, Inc. Methods for the treatment of addiction
ATE407117T1 (de) * 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US7686560B2 (en) * 2005-12-08 2010-03-30 Conestoga Cold Storage Rack, conveyor and shuttle automated pick system
MX2008014320A (es) * 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2009251816B2 (en) * 2008-05-27 2015-12-10 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders

Also Published As

Publication number Publication date
JP6943994B2 (ja) 2021-10-06
EP3251699A2 (en) 2017-12-06
US20200197383A1 (en) 2020-06-25
JP2020075938A (ja) 2020-05-21
EP4385575A2 (en) 2024-06-19
JP7288016B2 (ja) 2023-06-06
KR20190077590A (ko) 2019-07-03
JP2021193118A (ja) 2021-12-23
KR101994596B1 (ko) 2019-06-28
WO2016122218A2 (ko) 2016-08-04
EP4385575A3 (en) 2024-08-28
US20230293443A1 (en) 2023-09-21
ES2985064T3 (es) 2024-11-04
JP7594045B2 (ja) 2024-12-03
WO2016122218A3 (ko) 2016-10-13
DK3251699T3 (da) 2024-05-21
EP3251699B1 (en) 2024-04-17
US20250255823A1 (en) 2025-08-14
ES2985064T8 (en) 2025-03-07
CN114146088A (zh) 2022-03-08
CN107206093A (zh) 2017-09-26
KR20180015302A (ko) 2018-02-12
US12311056B2 (en) 2025-05-27
US20170326127A1 (en) 2017-11-16
KR20160103548A (ko) 2016-09-01
KR20220071297A (ko) 2022-05-31
JP2023109947A (ja) 2023-08-08
KR20200032759A (ko) 2020-03-26
EP3251699A4 (en) 2018-08-01
KR20210095734A (ko) 2021-08-02
JP2018503677A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
JP7288016B2 (ja) 神経精神系障害の治療のための組成物および方法
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
KR101122469B1 (ko) 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
Wilson et al. Classics in chemical neuroscience: pramipexole
CA3040889A1 (en) Methods of treating diseases resulting from a maladapted stress response
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
CN110494140A (zh) 用于自闭症谱系障碍药物治疗的方法
JP6181754B2 (ja) トゥレット症候群治療のための縮合ベンゾアゼピン
Burini et al. Current and emerging pharmaceutical strategies for the treatment and management of restless legs syndrome
WO2008033754A3 (en) Xanthine derivatives in methods and compositions for the treatment of vascular depression
Bowden et al. Characterization of tolerance to the anti-leakage effect of formoterol in rat airways
EP3545955A1 (en) Drug for treating cocaine addiction or preventing recurrence of same
JP2022502441A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
WO2024234014A1 (en) Sublingual spray formulations of psychedelics
RU2468799C1 (ru) Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов
NOVEL et al. NEUROPHARMACOLOGY OF NOVEL ERIK TE BEEK
HK40012398A (en) Drug for treating cocaine addiction or preventing recurrence of same
NZ718978A (en) Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190212

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190401

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200131

R150 Certificate of patent or registration of utility model

Ref document number: 6655090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250